Contrary to the Jokers opinion " its not about the money" it really is. PXS has a reducing cash buffer with only 2 additional drug trials on the horizon for skin and myleo. Myleo results early in 2024 and drug trials aren't cheap, been working with Fiona Wood since 2016 and need to initiate another trial. Cheapest source of funding is Shareholders IMO without significant sales to generate revenue. Gotta worry about the cash balance.
PXS Price at posting:
4.8¢ Sentiment: Sell Disclosure: Not Held
